Latest research on Carboplatin

An organoplatinum compound that possesses antineoplastic activity. [PubChem]

Latest findings

Among patients with ovarian cancer, the most common “standard” regimens in the FAS and PAS (n=157 and n=79, respectively) were Carboplatin plus Paclitaxel (29% in both populations) and Carboplatin plus Gemcitabine (9% and 11%, respectively). [source, 2016]
Carboplatin (17% and 20%), Paclitaxel (16% and 14%), Topotecan (12% and 9%), Gemcitabine (10% and 15%), and bevacizumab (10% and 11%) were the most commonly used agents in “non-standard” regimens (for FAS and PAS, respectively). [source, 2016]
Among patients with non-small cell lung cancer, the most common “standard” regimens in the FAS and PAS (n=221 and n=70, respectively) were Carboplatin plus Gemcitabine (16% in both populations), Carboplatin plus Pemetrexed (11% and 6%), and Cisplatin plus Vinorelbine (6% and 13%). [source, 2016]
Of these cases, UBUC patients with pT3 or pT4 stage tumors or with nodal involvement received cisplatin-based post-operative adjuvant chemotherapy, but patients with renal insufficiency obtained Carboplatin. [source, 2016]
Following progression on Carboplatin, Paclitaxel and bevacizumab therapy, he was enrolled in a clinical trial of anti-PD-1 therapy at which time his tumour was determined to be PD-L1 positive by IHC (>1% positivity). [source, 2016]
He was treated with Carboplatin and Paclitaxel, Pemetrexed and Erlotinib plus an anti-MET antibody before enrolling on a study of anti-PD1 therapy. [source, 2016]
Castells et al. [5] showed that MSC were able to protect ovarian cells from apoptosis in response to Carboplatin after stabilization of the apoptosis-inhibitory proteins. [source, 2016]
Cisplatin, Carboplatin, Docetaxel, Vinorelbine, Gemcitabine, Gefitinib and Erlotinib were obtained from SellekChem. [source, 2016]
MPE-derived primary cultures were analyzed for their sensitivity to different chemotherapeutic drugs used in conventional adenocarcinoma lung therapies, Cisplatin, Carboplatin, Gemcitabine, vinolrebine and Docetaxel. [source, 2016]
The majority of primary cultures was resistant to Cisplatin (10 out of 16 of them showed an EC50 higher than 20 μM), while we observed a greater degree of sensitivity to Carboplatin (only 5 out of 18 had an EC50 higher than 20 μM). [source, 2016]